Profile data is unavailable for this security.
About the company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
- Revenue in USD (TTM)0.00
- Net income in USD-18.85m
- Incorporated1996
- Employees11.00
- LocationCellectar Biosciences Inc100 Campus DriveFLORHAM PARK 07932United StatesUSA
- Phone+1 (608) 441-8120
- Fax+1 (608) 441-8121
- Websitehttps://www.cellectar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 8.00m | -- | 0.0445 | 0.0097 | 2.20 | 0.7511 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| cbdMD Inc | 19.19m | -4.38m | 8.51m | 42.00 | -- | 1.00 | -- | 0.4435 | -3.92 | -3.92 | 4.77 | 0.8104 | 1.83 | 2.83 | 18.96 | -- | -19.44 | -48.27 | -44.42 | -54.99 | 62.37 | 63.95 | -10.63 | -85.60 | 1.20 | -- | 0.00 | -- | -1.50 | -14.45 | 43.21 | -- | -32.56 | -- |
| Gelteq Ltd | 117.18k | -4.70m | 8.57m | 7.00 | -- | 0.7664 | -- | 73.13 | -0.4981 | -0.4981 | 0.0124 | 1.04 | 0.0078 | -- | 0.5155 | 16,740.08 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Biofrontera Inc | 37.17m | -17.57m | 9.09m | 92.00 | -- | -- | -- | 0.2445 | -1.84 | -1.84 | 4.07 | -0.2216 | 2.19 | 2.44 | 9.45 | 403,967.40 | -103.57 | -48.03 | -339.69 | -77.55 | 64.41 | 48.93 | -47.28 | -60.99 | 0.8033 | -47.48 | 2.37 | -- | 9.54 | 7.35 | 11.78 | -- | -35.51 | -- |
| Cuprina Holdings (Cayman) Ltd | 23.99k | -2.24m | 9.42m | 14.00 | -- | 1.55 | -- | 392.50 | -0.1232 | -0.1232 | 0.0013 | 0.283 | 0.0049 | 13.39 | 0.7976 | 1,713.68 | -44.56 | -- | -131.50 | -- | -69.27 | -- | -9,194.46 | -- | 3.58 | -306.25 | 0.0244 | -- | -52.05 | -- | -39.39 | -- | -- | -- |
| Integrated Biopharma Inc | 53.43m | 672.00k | 9.94m | 153.00 | 15.10 | 0.4849 | 10.04 | 0.186 | 0.0212 | 0.0212 | 1.71 | 0.6597 | 2.07 | 4.45 | 12.77 | 349,183.00 | 2.60 | 9.98 | 3.28 | 13.68 | 9.75 | 10.74 | 1.26 | 4.58 | 1.92 | -- | 0.0072 | -- | 8.02 | 0.5933 | 482.30 | -30.67 | -0.8556 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.05m | 233.00 | 0.0687 | 0.0011 | 2.60 | 0.142 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Bon Natural Life Ltd | 18.67m | -1.99m | 10.05m | 96.00 | 18.52 | 0.2302 | -- | 0.5385 | 0.088 | 0.088 | 6.74 | 7.08 | 0.2541 | 6.07 | 1.64 | 194,486.40 | -2.79 | 5.82 | -3.97 | 7.86 | 20.77 | 28.53 | -10.98 | 10.83 | 1.61 | -4.44 | 0.1735 | 0.00 | -21.70 | 0.4899 | -577.58 | -- | 18.20 | -- |
| Nexgel Inc | 11.67m | -2.88m | 10.75m | 19.00 | -- | 2.07 | -- | 0.9215 | -0.3796 | -0.3796 | 1.53 | 0.6369 | 1.05 | 3.79 | 13.46 | 613,947.40 | -25.14 | -39.08 | -36.83 | -49.79 | 38.30 | 19.60 | -23.91 | -105.40 | 1.08 | -51.36 | 0.1439 | -- | 112.47 | 64.69 | -3.93 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -15.77m | 11.08m | 8.00 | -- | -- | -- | -- | -0.600 | -0.600 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -65.57 | -112.46 | -136.47 | -257.78 | -- | -- | -- | -- | -- | -27.77 | 0.0854 | -- | -- | -- | -97.75 | -- | -- | -- |
| Cellectar Biosciences Inc | 0.00 | -18.85m | 14.16m | 11.00 | -- | 1.43 | -- | -- | -10.78 | -10.78 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -72.62 | -104.57 | -141.24 | -133.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.23 | -- | 33.54 | -- |
| Hoth Therapeutics Inc | 0.00 | -12.16m | 14.74m | 2.00 | -- | 1.75 | -- | -- | -1.06 | -1.06 | 0.00 | 0.5442 | 0.00 | -- | -- | 0.00 | -138.61 | -129.47 | -154.67 | -144.30 | -- | -- | -- | -- | -- | -493.48 | 0.00 | -- | -- | -- | -4.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 26.85m | -49.38m | 16.65m | 233.00 | -- | -- | -- | 0.6201 | -2.98 | -2.98 | 1.62 | -1.85 | 0.6096 | 1.60 | 4.22 | 115,218.90 | -107.02 | -36.27 | -277.91 | -51.90 | 53.68 | 57.36 | -175.56 | -124.01 | 0.236 | -13.27 | -- | -- | -15.77 | 47.19 | -45.62 | -- | -55.67 | -- |
| Lexaria Bioscience Corp | 522.00k | -10.79m | 16.97m | 7.00 | -- | 3.08 | -- | 32.50 | -0.5743 | -0.5743 | 0.0272 | 0.221 | 0.0659 | -- | 2.97 | 74,571.43 | -136.35 | -102.60 | -145.39 | -105.78 | 100.00 | 87.95 | -2,069.41 | -1,579.38 | -- | -285.30 | 0.00 | -- | 52.05 | 17.53 | -105.37 | -- | 48.50 | -- |
| Natural Alternatives International Inc | 134.44m | -11.88m | 20.51m | 293.00 | -- | 0.2971 | -- | 0.1525 | -1.99 | -1.99 | 22.52 | 11.17 | 0.845 | 4.35 | 7.36 | 458,839.60 | -7.47 | 0.4593 | -9.15 | 0.5479 | 8.50 | 12.75 | -8.84 | 0.4296 | 1.01 | -2.56 | 0.1408 | 0.00 | 14.12 | 1.78 | -88.10 | -- | -4.46 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 20.76m | 217.00 | -- | 0.1459 | -- | 6.53 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Cellectar Biosciences Inc's reporting currency: US Dollar USD
12.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 30 Sep 2025 | 100.00k | 3.74% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 71.98k | 2.69% |
| Sequoia Financial Advisors LLCas of 31 Dec 2025 | 25.35k | 0.95% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 24.90k | 0.93% |
| Geode Capital Management LLCas of 30 Sep 2025 | 24.89k | 0.93% |
| DRW Securities LLCas of 30 Sep 2025 | 21.10k | 0.79% |
| Citadel Securities LLCas of 30 Sep 2025 | 18.53k | 0.69% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 18.06k | 0.68% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 16.57k | 0.62% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 13.03k | 0.49% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
